SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 10, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

July 30, 2026

Conditions
Gastric Cancer
Interventions
DRUG

SOX+Tislelizumab+LDRT

"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."

All Listed Sponsors
lead

West China Hospital

OTHER

NCT06266871 - SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter